潞党参口服液联合乌苯美司治疗恶性肿瘤放化疗后免疫功能低下患者的疗效和依从性  

Efficacy and Compliance of Ludangshen Oral Liquid Combined with Ubenimex in Immunocompromised Patients after Radiotherapy and Chemoradiotherapy of Malignant Tumors

作　　者：曹婷[1,2] 肖红慧[1,2] CAO Ting;XIAO Hong-Hui(Oncology Department of Hubei Provincial Hospital of Traditional Chinese Medicine(Optics Valley branch courts),Wuhan 430070,China;Endocrinology Department of Hubei Provincial Hospital of Traditional Chinese Medicine,Wuhan 430070,China)

机构地区：[1]湖北省中医院(光谷院区)肿瘤科,武汉430070 [2]湖北省中医院内分泌科,武汉430070

出　　处：《中国药物经济学》2022年第12期58-61,65,共5页China Journal of Pharmaceutical Economics

摘　　要：目的 探讨潞党参口服液联合乌苯美司治疗恶性肿瘤放化疗后免疫功能低下患者的临床疗效及依从性。方法 选取2019年1月至2021年2月湖北省中医院收治的恶性肿瘤患者102例作为研究对象,按照随机数字表法分为观察组和对照组,各51例。对照组在常规放化疗的基础上联合使用乌苯美司进行辅助治疗,观察组在对照组基础上加用潞党参口服液进行辅助治疗,连续治疗12周。观察两组患者不同治疗方案的临床效果,比较两组患者治疗前后外周血T淋巴细胞亚群和NK细胞水平及依从性变化,观察两组患者治疗期间的不良反应。结果 观察组患者治疗有效率(64.70%)高于对照组(45.10%)(P<0.05);治疗后,两组患者CD3^(+)、CD4^(+)T淋巴细胞与NK细胞占比及CD4^(+)/CD8^(+)值均提高,CD8^(+)T淋巴细胞占比均下降,且观察组改善幅度均优于对照组,差异有统计学意义(P<0.05);观察组依从性优、良病例数占比均显著高于对照组(P<0.05);两组患者均未出现致命性不良反应,观察组发生Ⅲ度及以上白细胞减少病例数占比(15.69%)显著低于对照组(33.33%)(P<0.05),两组患者Ⅲ度及以上血小板减少、胃肠道反应、脱发、肝肾毒性反应、皮疹、神经毒性反应病例数占比差异无统计学意义(P>0.05)。结论 潞党参口服液联合乌苯美司能显著改善恶性肿瘤放化疗后患者免疫功能,疗效显著,对患者治疗依从性也有积极影响,且药物安全可靠。Objective To explore the efficacy and compliance of Ludangshen Oral Liquid combined with Ubenimex in iImmunocompromised patients after radiotherapy and chemoradiotherapy of malignant tumors. Methods A total of 102 patients with malignant tumors admitted to Hubei Provincial Hospital of Traditional Chinese Medicine from January 2019 to February 2021were selected as the study subjects, and randomly divided into the observation group and the control group, with 51 cases in each group. The control group received with Ubenimex on the basis of conventional radiotherapy and chemoradiotherapy, and the observation group was treated with Ludangshen Oral Liquid on the basis of the control group, total treatment was twelve weeks. The clinical effect of the different treatment regimens, the peripheral blood T lymphocyte subsets and NK cell levels before and after treatment, the changes in the compliance, and adverse reactions in the two groups were observed and compared. Results The effective rate of treatment in the observation group(64.70%) was higher than that in the control group(45.10%)(P<0.05);after treatment, the proportion of CD3^(+),CD4^(+)T lymphocytes and NK cells and CD4^(+)/CD8^(+) values increased in both groups, and the proportion of CD8^(+)T lymphocytes decreased, and the improvement in the observed group was better than that of the control group,which was statistically significant(P<0.05);the proportion of good compliance and good case number in the observation group was significantly higher than that in the control group(P<0.05);no cases of fatal adverse effects occurred in both patients, the proportion of leukopenia cases in the observed group(15.69%) was significantly lower than that in the control group(33.33%)(P<0.05), there was no significant difference in the proportion of cases of thrombocytopenia, gastrointestinal reaction, alopecia, liver and renal toxicity, rash, and neurotoxic reaction between the two groups(P<0.05). Conclusion Ludangshen Oral Liquid combined with Ubenimex can significantly improve

关 键 词：潞党参口服液 乌苯美司 恶性肿瘤 免疫功能 临床疗效 依从性 

分 类 号：R730.52[医药卫生—肿瘤] R730.51[医药卫生—临床医学]